
Relicitabine 500 Tablet
Marketer
Reliance Life Sciences
Salt Composition
Capecitabine (500mg)
Overview Relicitabine 500 Tablet
Relitab 500mg tablets are indicated for treating breast, colorectal, and rectal cancers. The physician may prescribe it for other conditions. This medication is administered alone or alongside other drugs as part of a chemotherapy regimen. Relitab 500mg tablets should be ingested with food, within 30 minutes post-meal. Dosage and frequency are determined by your doctor, depending on your condition and may be adjusted. Strictly adhere to your doctor's instructions; incorrect usage or overdose can lead to severe adverse effects. Therapeutic benefits may take weeks or months to manifest; discontinue only under medical supervision. Common side effects include nausea, vomiting, weakness, abdominal discomfort, and diarrhea. This medication can lower blood cell counts (especially white blood cells), increasing infection risk. Regular blood tests monitoring blood cell levels, along with heart, liver, and uric acid levels are crucial. Inform your doctor of any pre-existing liver or kidney issues, or concurrent use of infection-fighting medications. Interactions with other drugs are possible; disclose all medications to your doctor. Relitab 500mg is contraindicated during pregnancy and breastfeeding. Effective contraception for both partners is essential throughout treatment to prevent pregnancy.
Uses of Relicitabine 500 Tablet
Malignancies of the breast and colorectal system
Major Benefits of Relicitabine 500 Tablet:
Consume this medication precisely as directed by your physician, adhering to the prescribed dosage and treatment period. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Relicitabine 500mg tablets should be administered with a meal.
Common Side effects of Relicitabine 500 Tablet:
- Vomiting
- Weakness
- Nausea
- Abdominal pain
- Diarrhea
- Blisters on fingers/feet
How to use Relicitabine 500 Tablet:
Consume this medication precisely as directed by your physician, adhering to the prescribed dosage and treatment period. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. The Relicitabine 500 Tablet should be administered with a meal.
How Relicitabine 500 Tablet works:
Relicitabine 500mg tablets function as an antineoplastic agent. Metabolic processes transform this drug into 5-fluorouracil, which inhibits the production of essential genetic components (RNA and DNA) within cancerous cells. This disruption of cellular replication leads to a deceleration of tumor growth and ultimately, cellular death.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Relicitabine 500 Tablet lacks established safety data. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
Use of Relicitabine 500mg tablets is contraindicated during pregnancy due to established fetal risk. In exceptional, life-threatening circumstances, a physician may consider prescription if the potential benefits outweigh the known hazards. Physician consultation is mandatory.
Breast feedingUNSAFE
The use of Relicitabine 500 Tablets is contraindicated while breastfeeding due to potential infant toxicity. Studies indicate a risk of harm to the nursing infant.
DrivingUNSAFE
Taking Relicitabine 500mg tablets might cause drowsiness, blurred vision, or dizziness. Refrain from driving if you experience these effects.
KidneyCAUTION
Patients with kidney impairment should use Relicitabine 500 Tablet cautiously, as dose modification may be necessary. Severe kidney disease contraindicates the use of Relicitabine 500 Tablet; physician consultation is advised.
LiverCAUTION
Patients with liver impairment should use Relicitabine 500mg tablets cautiously, potentially requiring a modified dosage. Physician consultation is advised. Relicitabine 500mg tablets are contraindicated in individuals with severe renal dysfunction.
What if you forget to take Relicitabine 500 Tablet :
NA
Facts to Know About Relicitabine 500 Tablet
| Label | Value |
|---|---|
| Chemical Type | Modified Deoxycytidine |
| Developing Habits | No. |
| Treatment Category | Cancer treatments |
| Action Category | Metabolic inhibitors |
